GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (NAS:AADI) » Definitions » EPS (Diluted)

Aadi Bioscience (Aadi Bioscience) EPS (Diluted) : $-2.44 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience EPS (Diluted)?

Aadi Bioscience's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.60. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.44.

Aadi Bioscience's EPS (Basic) for the three months ended in Dec. 2023 was $-0.60. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.44.

Aadi Bioscience's EPS without NRI for the three months ended in Dec. 2023 was $-0.60. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.44.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Aadi Bioscience EPS (Diluted) Historical Data

The historical data trend for Aadi Bioscience's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience EPS (Diluted) Chart

Aadi Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
-0.21 -12.41 -2.69 -2.44

Aadi Bioscience Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.52 -0.57 -0.67 -0.60 -0.60

Competitive Comparison of Aadi Bioscience's EPS (Diluted)

For the Biotechnology subindustry, Aadi Bioscience's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aadi Bioscience's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aadi Bioscience's PE Ratio distribution charts can be found below:

* The bar in red indicates where Aadi Bioscience's PE Ratio falls into.



Aadi Bioscience EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Aadi Bioscience's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-65.765-0)/26.918
=-2.44

Aadi Bioscience's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-16.269-0)/26.966
=-0.60

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aadi Bioscience  (NAS:AADI) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Aadi Bioscience EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aadi Bioscience (Aadi Bioscience) Business Description

Traded in Other Exchanges
Address
17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.
Executives
Neil Desai director, officer: See Remarks C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
David James Lennon director, officer: Chief Executive Officer C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD, SUITE A250, PACIFIC PALISADES CA 90272
Mohammad Hirmand director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Scott M. Giacobello officer: Chief Financial Officer SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB24 9BZ
Lorettta M Itri officer: Chief Medical Officer
Brendan Delaney officer: Chief Operating Officer 300 THE AMERICAN WAY, MORRIS PLAINS NJ 07950
Emma Reeve director C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Karin M. Hehenberger director C/O CORONADO BIOSCIENCES, INC., 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON CO 01803
Richard E Maroun director C/O AADI BIOSCIENCE, INC., 17383 SUNSET BLVD., SUITE A250, PACIFIC PALISADES CA 90272
Caley Castelein director THOM. WEISEL HEALTHCARE VENTURES, ONE MONTGOMERY STREET, SAN FRANCISCO CA 94104
Lance E Thibault officer: Chief Financial Officer
Behzad Aghazadeh director, other: See Remarks C/O AVORO CAPITAL ADVISORS LLC, 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Venbio Select Advisor Llc director, other: See Remarks 110 GREENE STREET, SUITE 800, NEW YORK NY 10012
Anupam Dalal director 88 KEARNY STREET, SUITE 1800, SAN FRANCISCO CA 94108
Avoro Ventures Llc director, other: See Remarks 110 GREEN STREET, SUITE 800, NEW YORK NY 10012